Exploring a new treatment target for myelofibrosis
Official title: MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11089310 · Data updated 2026-11-12
This study is looking at a new way to help people with myelofibrosis, a tough blood cancer, by exploring how a protein called MYC affects the disease and finding new treatments for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $553,041 |
| NIH project number | 5R01CA280116-02 |
| Project ID | NIH-11089310 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myelofibrosis, particularly those who have not responded adequately to current JAK2 inhibitor therapies.
✕Less likely to help
Patients with myelofibrosis who have already responded well to existing treatments may not benefit from this research.
What this research studies
This research investigates the MYC-alarmin axis as a potential new therapeutic target for patients with myelofibrosis, a serious blood cancer characterized by bone marrow fibrosis and a high risk of transformation to acute myeloid leukemia. The study aims to understand how MYC, a protein involved in cell growth and survival, contributes to the disease and how targeting this pathway could improve treatment outcomes. By analyzing genetic mutations and their effects on disease progression, the research seeks to develop innovative therapies that could benefit patients who do not respond well to existing treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival and quality of life for patients with myelofibrosis.
How similar studies have gone: While the MYC-alarmin axis is a novel approach in the context of myelofibrosis, similar strategies targeting oncogenic pathways have shown promise in other hematologic malignancies.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Yun, Seongseok — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Yun, Seongseok
Related research
Other NIH-funded projects on the same topics.
-
Strategies to deplete myelofibrosis stem cells using HDM2/p53 pathway
A patient-focused program tests a therapy that may selectively reduce disease-causing blood stem cells in people with myelofibrosis.
-
Megakaryocyte changes in myelofibrosis and its progression to leukemia
A scientist-guided project will study how abnormal megakaryocytes and signals like TGF-β and IL-13 may drive progression from myelofibrosis toward acute leukemia, with potential implications for future treatments.
-
Molecular clues and new therapies for myelofibrosis and related blood cancers
This grant supports research to understand what drives myelofibrosis and related disorders and to develop new treatment ideas for patients.
-
Myelofibrosis and the bone marrow environment: how inflammation changes blood production
A doctor-researcher is studying how inflammation in the bone marrow affects the blood-forming system in people with myeloproliferative neoplasms (MPNs) to find ways to prevent scarring and leukemia.
-
Early detection of treatment response in myelofibrosis using a new imaging technology
A new, quick imaging method could tell patients with myelofibrosis early whether a treatment is working.
-
MYC-driven vulnerability in myelofibrosis could guide new therapies
A new project is exploring how the MYC protein contributes to myelofibrosis and whether it can be targeted to help people with this blood cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.